Early Routine Eptifibatide Use is Not Superior to Delayed Provisional Use in NSTE ACS

Summary

The early routine administration of eptifibatide is not superior to delayed provisional eptifibatide use among invasively managed patients with high-risk non-ST-segment elevation acute coronary syndrome (NSTE ACS), according to findings from the Early Glycoprotein IIb/IIIa Inhibition in Non-ST-Segment Elevation Acute Coronary Syndromes [EARLY-ACS; NCT00089895] study. Moreover, compared with delayed use, early eptifibatide use increases bleeding and transfusion rates.

  • Myocardial Infarction Clinical Trials
View Full Text